​

•  Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023;200(2):240-248.  

• Gunsolley JC, Chalmers JD, Sibila O, Fernandez C, Scannapieco FA. Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis. JDR Clin Trans Res. 

• Hagen M, Shanga G, Caron S, Debnath, G. Nasal cast deposition for xylo- and oxymetazoline formulations using two different nasal pumps. Rhinology online, 2023;6:11-17

• Gwaltney C, Bean S, Venerus M, et al. Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver Diseases. Adv Ther. 2022;39(11):5126-5143. 

• Januzzi JL, Garasic JM, Kasner SE, et al. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022;15(1):1. 

• Pittman DD, Rakhe S, Bowley SR, Jasuja R, Barakat A, Murphy JE. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022;6(2):e12679 .